Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
First Shanghai Investments Limited, a diversified investment conglomerate, maintains diverse operations spanning financial services, real estate and hospitality, medical and healthcare, and direct investments. The company holds a global footprint, conducting business across Hong Kong, mainland China, and various international markets. Its robust financial division delivers a comprehensive suite of services, including securities investment and brokerage, margin financing, corporate finance, underwriting and placements, asset and wealth management, IPO subscriptions, custodian and nominee services, financial intermediation, and investment advisory. This segment further extends to money lending, financial leasing, consultancy, and internet financial service systems, alongside futures, stock, and insurance broking. The company's property and hotel interests encompass the development of a broad spectrum of real estate, from residential and serviced apartments to commercial offices, industrial spaces, hotels, and recreational resorts. It also directly operates hotels and golf courses. In the medical and healthcare sector, First Shanghai Investments is involved in the development and commercialization of therapeutic drugs. It also manages a medical center in Central, Hong Kong, which provides extensive services such as imaging, day surgery, endoscopy, health check-ups, medical beauty treatments, and general and specialist consultations, in addition to offering dental services. Beyond these core areas, the company also engages in container transportation and freight forwarding services. Established in 1964 and headquartered in Central, Hong Kong, the firm was formerly known as Public International Investments Limited, adopting its current name, First Shanghai Investments Limited, in June 1993.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.